HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: P&G stock buyback

This article was originally published in The Rose Sheet

Executive Summary

P&G stock buyback: Procter & Gamble plans to repurchase up to 11 mil. shares of its outstanding common stock, with a total value of $1 bil., during FY 1996-1997. The company noted that this plan is in addition to the annual repurchasing program of 4-5 mil. common shares announced in 1995 ("The Rose Sheet" April 3, 1995, In Brief). P&G explained that its "strong cash position and modest level of acquisition activity" during 1995-1996 are allowing it to initiate the buyback program. In commenting on the repurchase, the company said it is "committed to delivering superior total shareholder return through investments in [its] existing business, through targeted strategic acquisitions and through investing in [its] common stock"...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS002991

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel